Rare Opportunity: VC Invested in Niche Disease Space Stays Strong
December 04, 2014
As evidenced by Audentes Therapeutics' recent $42.5 million Series B financing, venture capital invested in companies focused on rare disease treatments has been plentiful this year, building on 2013's decade-high levels (for both deal count and capital invested). With only a month to go, 2014 is set to almost match last year's total of $287 million invested. Deal flow has fallen off somewhat from 2013's spurt of financing activity, but the money has continued to flow, with median deal size hitting $15.5 million this year, a level not reached since 2008. As advances in gene therapy continue, enabling ever more personalized investigation into drugs targeting niche diseases, VC interest in the space may well remain elevated.
To learn more about accessing the data behind this trend, click here.